Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, K.H. | - |
dc.contributor.author | Cho, J. | - |
dc.contributor.author | Han, B. | - |
dc.contributor.author | Kim, S.H. | - |
dc.contributor.author | Shin, D.-Y. | - |
dc.contributor.author | Hong, J. | - |
dc.contributor.author | Kim, H. | - |
dc.contributor.author | Kim, H.J. | - |
dc.contributor.author | Zang, D.Y. | - |
dc.contributor.author | Yoon, S.-S. | - |
dc.contributor.author | Jin, J.-Y. | - |
dc.contributor.author | Lee, J.H. | - |
dc.contributor.author | Hong, D.-S. | - |
dc.contributor.author | Park, S.K. | - |
dc.date.available | 2020-09-03T04:35:39Z | - |
dc.date.created | 2020-08-14 | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78132 | - |
dc.description.abstract | PURPOSE: We evaluated the outcomes of decitabine as first-line treatment in older patients with acute myeloid leukemia (AML) and investigated the predictors, including a baseline mini nutritional assessment short form (MNA-SF) score, of response and survival. PATIENTS AND METHODS: Between 2010 and 2018, 96 AML patients aged 65 and above who received decitabine treatment at 6 centers in Korea were retrospectively evaluated. Response rates, hematologic improvements (HI), progression-free survival (PFS), and overall survival (OS) were analyzed. RESULTS: The median age at diagnosis was 73.9 years, and the median number of decitabine treatments administered to the patients was 4 (range, 1-29). Of 85 patients, 15 patients (17.6%) achieved complete remission (CR) or CR with incomplete blood count recovery. Twelve patients (14.1%) showed partial remission (PR), and 18 (21.2%) demonstrated HI without an objective response. The median PFS and OS were 7.0 (95% confidence interval [CI], 4.9-9.0) and 10.6 (95% CI, 7.7-13.5%) months, respectively. In multivariate analyses, MNA-SF score ≥ 8 and the absence of peripheral blood (PB) blasts were significant predictors for improved PFS and OS. CONCLUSIONS: For older patients with newly diagnosed AML, a high MNA-SF score and the absence of PB blasts were independently associated with improved survival. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.relation.isPartOf | PloS one | - |
dc.title | Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000561027200050 | - |
dc.identifier.doi | 10.1371/journal.pone.0235503 | - |
dc.identifier.bibliographicCitation | PloS one, v.15, no.8, pp.e0235503 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85089170358 | - |
dc.citation.startPage | e0235503 | - |
dc.citation.title | PloS one | - |
dc.citation.volume | 15 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Yoo, K.H. | - |
dc.contributor.affiliatedAuthor | Kim, H. | - |
dc.contributor.affiliatedAuthor | Lee, J.H. | - |
dc.type.docType | Article | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.